Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry

Suhexiang pill for acute ischemic stroke in real-world practice setting (SUNRISE): protocol of a multicenter registry

Abstract Background Suhexiang (SHX) pill is widely used for treating acute ischemic stroke (AIS). Experimental and randomized controlled trials suggested that SHX pill was beneficial for patients with AIS. However, the effectiveness of SHX pill in real-world practice setting remains unclear. It is o...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinxing Lai, Xuejiao Xiong, Qi Jia, Tingting Liu, Zhaowen Yang, Chi Zhang, Lingbo Kong, Kegang Cao, Ting Dong, Caixia Fang, Jianwen Ge, Li Dong, Zhitao Zong, Sisi Chen, Yuhong Ma, Xue Bai, Dahua Wu, Yao Xie, Mingyan Zhang, Yilong Wang, Guohui Jiang, Daqiao Song, Yanping Wang, Chunyan Gui, Qingwen Geng, Ying Gao, for the SUNRISE study investigators
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Acute ischemic stroke
Suhexiang pill
Traditional Chinese medicine
Real world
Registry
Online Access:https://doi.org/10.1186/s12906-025-04762-9
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Suhexiang (SHX) pill is widely used for treating acute ischemic stroke (AIS). Experimental and randomized controlled trials suggested that SHX pill was beneficial for patients with AIS. However, the effectiveness of SHX pill in real-world practice setting remains unclear. It is of great importance to investigate the effectiveness and safety of SHX pill in patients with acute ischemic stroke in real-world clinical practice with long-term follow-up. Methods The Suhexiang pill for acute ischemic stroke in Real-world Practice Setting (SUNRISE) is a multicenter, prospective, product-specific, observational study designed to provide insight into the administration of SHX pill for patients with AIS in the real-world clinical practice setting, with an initial sample size of 1000. Eligible patients treated with SHX pill within seven days of AIS onset will be consecutively included in this registry. The primary outcome is the proportion of patients independent at 3 months after stroke onset defined by an mRS score of 0, 1, or 2. Conclusion The findings of the SUNRISE registry will not only provide insights into the characteristics of patients who may benefit from SHX treatment, but also may enable the individualized treatment decision-making of SHX pill in real-world practice setting. Study registration This study was registered with the ClinicalTrials.gov (URL: https://clinicaltrials.gov/ , Unique identifier: NCT05833932).
ISSN:2662-7671

Similar Items